Navigation Links
Asymmetrex Director Comments on Positive Attributes of Private Stem Cell Clinics
Date:6/8/2017

In a new early view article published in the online Journal of Stem Cell Research and Medicine, James L. Sherley, M.D., Ph.D., founder and director of Asymmetrex, LLC, asks the question, “Why are patients scared away from private stem cell clinics?” (May 6, 2017). Sherley presents a critical assessment of the warnings pronounced by federal agencies and professional organizations, like the National Institutes of Health (NIH) and the International Society for Stem Cell Research (ISSCR), against private clinics providing stem cell treatments. He argues that new treatments in private clinics are, for the most part, not very different than stem cell treatments in clinical trials authorized by the Food and Drug Administration (FDA).

In his comment, Sherley chides the NIH, ISSCR, and alarmist commentators for portraying private stem cell clinics, as a group, as unethical, and even dangerous to patients, without good evidence to support their claims. He provides examples to show that many operational elements of stem cell treatments in private clinics are not unlike FDA-authorized clinical trials. Both stem cell treatment settings have strengths and weaknesses. Sherley’s position is that, “In their missions to serve patients, the NIH’s and ISSCR’s efforts would seem to be better spent informing patients how to obtain the best care in either setting.” In earlier writings and presentations, he has also urged decision-makers to develop policies for collecting, organizing, and studying stem cell treatment data from private clinics. Since the number of patients treated in private clinics is now estimated to far exceed the number in clinical trials, Sherley has argued that excluding this valuable experience by vilifying it is a tragic loss to stem cell medical research and patients.

A crucial way in which FDA-authorized clinical trials and private stem cell treatment clinics are not different is their past lack of a means to determine the dose and quality of stem cell treatments. In his published comment, Sherley notes that none of the anti-private clinic alarmists acknowledges this deficiency that also impacts the worth of stem cell clinical trials. In fact, this need even limits the quality of some approved stem cell therapies like umbilical cord blood stem cell transplant.

Asymmetrex has recently developed a technological solution for the half century-old problem of specifically counting tissue stem cells. With the company’s new technology, it is now possible to determine the dose and quality of therapeutic tissue stem cell preparations. Asymmetrex is positioned to become the certifying agency for the dose and quality of tissue stem cells used in approved treatments and either FDA-authorized clinical trials or private stem cell clinic treatments. Sherley predicts that adoption of this shared certification process will promote a more reasoned assessment of the contributions that private stem cell clinics are and can make to accelerating progress in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14406590.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells
2. New Commentary from Asymmetrex LLC Director Anticipates Forthcoming E-Book on “Stem Cell Genetic Fidelity”
3. Boston Stem Cell Biotech Start-up Asymmetrex Will Present Essential Technologies for Stem Cell Medical Engineering at Chicago Stem Cell Research Conference
4. Asymmetrex Opens Up 5th World Congress on Cell and Stem Cell Research in Chicago with a Focus on Its New Technologies for Stem Cell Medical Engineering
5. Asymmetrex Interviewed in Anticipation of Presentations at the 14th Annual World Preclinical Congress Focused on Tackling Translation Challenges
6. Asymmetrex Launches a Crowdsourcing Campaign to Introduce New Biomarkers for Counting Previously Elusive Tissue Stem Cells
7. In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells
8. Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June
9. Asymmetrex Introduces “The Third Dimension of Time” to 3D Cell Modelers at the 14th Annual World Preclinical Congress in Boston
10. Asymmetrex’s Crowdsourcing Campaign For Evaluating A First Biomarker for Counting Adult Tissue Stem Cells Is Gaining Momentum
11. Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):